FindTrial
Sign In

Relacorilant 150 mg once daily (QD)

DRUG3 trials

Sponsors

Corcept Therapeutics

Conditions

AdenocarcinomaCarcinoma, Pancreatic DuctalEndometrial CancerFallopian Tube CancerFallopian Tube NeoplasmsOvarian CancerOvarian NeoplasmPeritoneal Neoplasms

Phase 2

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RecruitingNCT06906341
Corcept TherapeuticsEndometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1
Start: 2025-04-11End: 2026-12-31Target: 270Updated: 2025-10-22
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingNCT07259317
Corcept TherapeuticsAdenocarcinoma, Carcinoma, Pancreatic Ductal
Start: 2026-01-27End: 2027-07-01Target: 60Updated: 2026-03-27

Phase 3

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Active, not recruitingNCT05257408
Corcept TherapeuticsFallopian Tube Neoplasms, Ovarian Neoplasm, Peritoneal Neoplasms
Start: 2022-06-29End: 2026-03-31Updated: 2025-04-16

Related Papers

ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).
Journal of Clinical Oncology2025-06-043 citations
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
2025-06-0212 citations
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.
2024-07-015 citations
TP019/#1387  Rosella (GOG-3073, ENGOT-OV72/MITO): a phase 3 study of relacorilant + nab paclitaxel vs. nab-paclitaxel in platinum-resistant ovarian cancer
2023-11-011 citations
#205 ROSELLA (GOG-3073, ENGOT-Ov72/MITO): a phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer
2023-09-013 citations
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
Journal of Clinical Oncology2023-06-2631 citations
Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Journal of Clinical Oncology2022-06-086 citations